Ireland
--:--IST
Recruiting Not applicable

Effect of Strength-resistance Exercise in the Reduction of Gestational Diabetes in Pregnant Women with Overweight or Obesity

NCT05840497 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2023-03-01
Last updated
2024-11-22

Condition(s) studied

Diabetes, Gestational

Investigational drug(s) / intervention(s)

Resistance exercise

Resistance exercise: The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself. Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions. .

Study summary

The aim of this trial is to test the efficacy of regular resistance exercise in early pregnancy to prevent gestational diabetes mellitus in overweight/ obese pregnant women.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * BMI≥25 kg/m2 * Singleton pregnancies Exclusion Criteria: * Chronic hypertension * Pre-pregnancy DM (type I or 2 diabetes mellitus) * Cardiovascular disease * History of preterm delivery

Primary outcome measure(s)

  • Gestational diabetes — 24-28 gestational weeks
    Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy: * O'Sullivan Test: if this is pathological; * SOG with 100 gr of glucose (GDM is diagnosed when 2 or more altered values: basal glycemia \>105 mg / dl, at 1 hour \>190 mg / dl, at 2h glycemia \>165 mg / dl, at 3h glycemia \>145 gr/dl).

Trial sites (1)

FacilityCityRegionStatus
Fundación Miguel Servet/Navarrabiomed Pamplona Navarre Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05840497 on ClinicalTrials.gov ↗ ← All trials in Spain